Ki-67 is a valuable prognostic factor in gliomas: Evidence from a systematic review and meta-analysis

Asian Pacific Journal of Cancer Prevention

Volumn 16, Issue 2, 2015, Pages 411-420

  Chen, Wen Jie ^a   He, De Shen ^b   Tang, Rui Xue ^a   Ren, Fang Hui ^a   Chen, Gang ^a  

^a FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Glioma; Immunohistochemistry; Ki 67; Meta analysis; Prognosis; Survival

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER;

BRAIN TUMOR; CASE CONTROL STUDY; GLIOMA; HUMAN; META ANALYSIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; GLIOMA; HUMANS; KI-67 ANTIGEN; PROGNOSIS; SURVIVAL RATE;

EID: 84925411798     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2015.16.2.411     Document Type: Article

References (67)

1. Abd El Atti RM, Abou Gabal HH, Osman WM, et al (2013). Insights into the prognostic value of DJ-1 and MIB-1 in astrocytic tumors. Diagn Pathol, 8, 126.
2. Armstrong TS, Vera-Bolanos E, Bekele BN, et al (2010). Adult ependymal tumors: prognosis and the M.D. anderson cancer center experience. Neuro Oncol, 12, 862-70.
3. Bowers DC (2003). Study of the MIB-1 labeling index as a predictor of tumor progression in pilocytic astrocytomas in children and adolescents. J Clin Oncol, 21, 2968-73.
4. Bredel M, Piribauer M, Marosi C, et al (2002). High expression of DNA topoisomerase IIa and Ki-67 antigen is associated with prolonged survival in glioblastoma patients. European J Cancer, 38, 1343-7.
5. Ho DM, Hsu CY, Ting LT, Chiang H, et al (2003). MIB-1 and DNA topoisomerase IIa could be helpful for predicting long-term survival of patients with glioblastoma. Am J Clin Pathol, 119, 715-22.
6. Coons SW, Johnson PC, Pearl DK (1997). The prognostic significance of Ki-67 labeling indices for oligodendrogliomas. Neurosurgery, 41, 878-85.
7. Dang YW, Zeng J, He RQ, et al (2014). Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells. Asian Pac J Cancer Prev, 15, 4969-76.
8. Dehghani F, Schachenmayr W, Laun A, et al (1998). Prognostic implication of histopathological, immunohistochemical and clinical features of oligodendrogliomas: a study of 89 cases. Acta Neuropathologica, 95, 493-504.
9. Donato V, Papaleo A, Castrichino A, et al (2007). Prognostic implication of clinical and pathologic features in patients with glioblastoma multiforme treated with concomitant radiation plus temozolomide. Tumori, 93, 248.
10. Ellison DW, Steart PV, Bateman AC, et al (1995). Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry, 59, 413-9.
11. Fakhrjou A, Dastranj-Tabrizi A, Ghojazadeh M, et al (2013). Diagnostic value of protein Ki67 (MIB-1) in atypical Pap smears of postmenopausal women. Asian Pac J Cancer Prev, 14, 4815-8.
12. Figarella-Branger D, Civatte M, Bouvier-Labit C, et al (2000). Prognostic factors in intracranial ependymomas in children. J Neurosurg, 93, 605-13.
13. Habberstad AH, Gulati S, Torp SH (2011). Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIa in human anaplastic astrocytomas-an immunohistochemical study. Diagn Pathol, 6, 43.
14. Haroon S, Hashmi AA, Khurshid A, et al (2013). Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev, 14, 4353-8.
15. Heegaard S, Sommer HM, Broholm H, et al (1995). Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer, 76, 1809-13.
16. Hernandez-Pedro NY, Rangel-Lopez E, Magana-Maldonado R, et al (2013). Application of nanoparticles on diagnosis and therapy in gliomas. Biomed Res Int, 2013, 351031.
17. Higgins J, Thompson SG (2002). Quantifying heterogeneity in a meta-analysis. Statistics in medicine, 21, 1539-58.
18. Ho DM-T, Hsu C-Y, Wong T-T, et al (2001). A clinicopathologic study of 81 patients with ependymomas and proposal of diagnostic criteria for anaplastic ependymoma. J Neuro-Oncol, 54, 77-85.
19. Hu X, Miao W, Zou Y, et al (2013). Expression of p53, epidermal growth factor receptor, Ki-67 and O6-methylguanine-DNA methyltransferase in human gliomas. Oncol Letters, 6, 130-4.
20. Huang S, Chen G (2014). Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. Scientific World J, 2014, 605236.
21. Huang T, Jin X, He L, et al (2013). Role of podocalyxin in astrocytoma: clinicopathological and evidence. Oncol Lett, 6, 1390-6.
22. Jaros E, Perry R, Adam L, et al (1992). Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumours. Br J Cancer, 66, 373.
23. Kanamori M, Kumabe T, Sonoda Y, et al (2008). Predictive factors for overall and progression-free survival, and dissemination in oligodendroglial tumors. J Neuro-Oncol, 93, 219-28.
24. Kleinschmidt-DeMasters BK, Meltesen L, McGavran L, et al (2006). Characterization of glioblastomas in young adults. Brain Pathology, 16, 273-86.
25. Kohler BA, Ward E, McCarthy BJ, et al (2011). Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst, 103, 714-36.
26. Kouri FM, Jensen SA, Stegh AH (2012). The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond. Scientific World J, 2012, 838916.
27. Kros JM, Hop WC, Godschalk JJ, et al (1996). Prognostic value of the proliferation-related antigen Ki-67 in oligodendrogliomas. Cancer, 78, 1107-13.
28. Kuo LT, Kuo KT, Lee MJ, et al (2009). Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer, 124, 2872-9.
29. Laks DR, Masterman-Smith M, Visnyei K, et al (2009). Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells, 27, 980-7.
30. Lau J, Ioannidis JP, Schmid CH (1997). Quantitative synthesis in systematic reviews. Ann Intl Med, 127, 820-6.
31. Li S-W, Qiu X-G, Chen B-S, et al (2009). Prognostic factors influencing clinical outcomes of glioblastoma multiforme. Chin Med J, 122, 1245-9.
32. Liu Y, Tang K, Yan W, et al (2013). Identifying Ki-67 specific miRNA-mRNA interactions in malignant astrocytomas. Neuroscience Letters, 546, 36-41.
33. Margraf LR, Gargan L, Butt Y, et al (2011). Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas-an assessment of 3 new variables in predicting clinical outcome. Neuro Oncol, 13, 767-74.
34. McKeever PE, Strawderman MS, Yamini B, et al (1998). MIB-1 proliferation index predicts survival among patients with grade II astrocytoma. J Neuropathol Exp Neurol, 57, 931-6.
35. Montine TJ, Vandersteenhoven JJ, Aguzzi A, et al (1994). Prognostic significance of Ki-67 proliferation index in supratentorial fibrillary astrocytic neoplasms. Neurosurgery, 34, 674-9.
36. Nabika S, Kiya K, Satoh H, et al (2010). Prognostic significance of expression patterns of EGFR family, p21 and p27 in high-grade astrocytoma. Hiroshima J Med Sci, 59, 65-70.
37. Nazarenko I, Hede SM, He X, et al (2012). PDGF and PDGF receptors in glioma. Ups J Med Sci, 117, 99-112.
38. Neder L, Colli B, Machado H, et al (2003). MIB-1 labeling index in astrocytic tumors-a clinicopathologic study. Clin Neuropathol, 23, 262-70.
39. Okita Y, Narita Y, Miyakita Y, et al (2012). Pathological findings and prognostic factors in recurrent glioblastomas. Brain Tumor Pathol, 29, 192-200.
40. Park KJ, Kang SH, Park DH, et al (2012). Usefulness of thallium-201 SPECT for prediction of early progression in low-grade astrocytomas diagnosed by stereotactic biopsy. Clin Neurol Neurosurg, 114, 223-9.
41. Parmar MK, Torri V, Stewart L (1998). Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17, 2815-34.
42. Phi JH, Wang KC, Park SH, et al (2012). Pediatric infratentorial ependymoma: prognostic significance of anaplastic histology. J Neurooncol, 106, 619-26.
43. Pollack IF, Campbell JW, Hamilton RL, et al (1997). Proliferation index as a predictor of prognosis in malignant gliomas of childhood. Cancer, 79, 849-56.
44. Pollack IF, Hamilton RL, Burnham J, et al (2002). Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery, 50, 1238-45.
45. Preusser M, Hoeftberger R, Woehrer A, et al (2012). Prognostic value of Ki67 index in anaplastic oligodendroglial tumours-a translational study of the European organization for research and treatment of cancer brain tumor group. Histopathology, 60, 885-94.
46. Preusser M, Wolfsberger S, Czech T, et al (2005). Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. Am J Clin Pathol, 124, 543-9.
47. Qiang J, Wei Z, Xiao-Guang Q, et al (2011). Gene expression profiling reveals Ki-67 associated proliferation signature in human glioblastoma. Chinese Med J Beijing, 124, 2584.
48. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al (2001). The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neuro-Oncol, 55, 195-204.
49. Ritter AM, Hess KR, McLendon RE, et al (1998). Ependymomas: MIB-1 proliferation index and survival. J Neurooncol, 40, 51-7.
50. Rodriguez-Pereira C, Suarez-Penaranda J, Vazquez-Salvado M, et al (2000). Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study. J Neurosurg Sci, 44, 203-9; discussion 9-10.
51. Shen C, Yang L, Yuan X (2011). Endothelin B receptor expression in human astrocytoma: association with clinicopathological variables and survival outcomes. Int J Neurosci, 121, 626-31.
52. Tadbir AA, Pardis S, Ashkavandi ZJ, et al (2012). Expression of Ki67 and CD105 as proliferation and angiogenesis markers in salivary gland tumors. Asian Pac J Cancer Prev, 13, 5155-9.
53. Tian B, Zhang Y, Zhang J (2014). Periostin is a new potential prognostic biomarker for glioma. Tumour Biol, 35, 5877-83.
54. Torp S, Helseth E, Dalen A, et al (1992). Relationships between Ki-67 labelling index, amplification of the epidermal growth factor receptor gene, and prognosis in human glioblastomas. Acta Neurochirurgica, 117, 182-6.
55. Tove L-L, Hanssøn HA, Stein S, et al (2012). Prognostic value of histological features in diffuse astrocytomas WHO grade II. Interl J Clin Experimental Pathol, 5, 152.
56. Uematsu M, Ohsawa I, Aokage T, et al (2005). Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index. J Neurooncol, 72, 231-8.
57. Watanabe Y, Yamasaki F, Kajiwara Y, et al (2010). Expression of phosphoprotein enriched in astrocytes 15 kDa (PEA-15) in astrocytic tumors: a novel approach of correlating malignancy grade and prognosis. J Neurooncol, 100, 449-57.
58. Wen PY, Kesari S (2008). Malignant gliomas in adults. New England J Med, 359, 492-507.
59. Wessels PH, Hopman AH, Kubat B, et al (2003). Proliferation and aneusomy predict survival of young patients with astrocytoma grade II. Br J Cancer, 89, 128-34.
60. Westermark B (2012). Glioblastoma-a moving target. Ups J Med Sci, 117, 251-6.
61. Yang P, Wang Y, Peng X, et al (2013). Management and survival rates in patients with glioma in China (2004-2010): a retrospective study from a single-institution. J Neurooncol, 113, 259-66.
62. Yoshida Y, Nakada M, Harada T, et al (2010). The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients. J Neurooncol, 98, 41-7.
63. Yue Q, Zhang X, Ye HX, et al (2014). The prognostic value of Foxp3+ tumor-infiltrating lymphocytes in patients with glioblastoma. J Neurooncol, 116, 251-9.
64. Zamecnik J, Snuderl M, Eckschlager T, et al (2003). Pediatric intracranial ependymomas: prognostic relevance of histological, immunohistochemical, and flow cytometric factors. Modern Pathol, 16, 980-91.
65. Zawrocki A, Izycka-Swieszewska E, Papierz W, et al (2011). Analysis of the prognostic significance of selected morphological and immunohistochemical markers in ependymomas, with literature review. Folia Neuropathol, 49, 94-102.
66. Zhao S, Wu J, Wang C, et al (2013). Intraoperative fluorescence-guided resection of high-grade malignant gliomas using 5-aminolevulinic acid-induced porphyrins: a systematic review and meta-analysis of prospective studies. PLoS One, 8, e63682.
67. Zhong D, Li X, Zhang G (2001). Multivariate analysis of the parameters related to prognosis of astrocytoma. Zhonghua Bing Li Xue Za Zhi Chinese J Pathol, 30, 345-9.